PRECURSOR LESIONS AND ORAL CANCER TUMORIGENESIS: A PATHOGENETIC MODEL OF SURVIVIN-DEPENDENT MOLECULAR SIGNALLING PATHWAYS
Main Article Content
Keywords
.
Abstract
Introduction: The p53 tumor suppressor gene regulates cellular growth in response to DNA damage by inducing G1 arrest and apoptosis. Survivin, an apoptosis inhibitor, inhibits caspases and modulates the cell cycle, primarily found in minimal amounts in mature tissues. The aberrant expression of p53 and survivin has been explored in various carcinomas.
Objectives: The basic aim of the study is to investigate the co-expression of p53 and survivin in tissue samples from Oral Potentially Malignant Disorders (OPMDs) and Oral Squamous Cell Carcinoma (OSCCs).
Methodology: The study utilized 50 tissue samples each from OPMDs and OSCCs obtained from department archives. Immunohistochemistry was employed to assess the expression of p53 and survivin in the study groups, alongside the evaluation of their co-expression.
Results: The oral epithelium of patients with OSCCs exhibited significantly higher expression levels of p53 and survivin compared to patients with OPMDs (P value ≤0.05).
Conclusion: It is concluded that altered co-expression of survivin and p53, indicating significant immune expression. These markers could serve as valuable indicators for cell proliferation and the apoptotic pathway.
References
2. Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A review of HPV-related head and neck cancer. J Clin Med. (2018) 7:241. doi: 10.3390/jcm7090241
3. Maleki Vareki S, Salim KY, Danter WR, Koropatnick J. Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines. PLoS ONE. (2018) 13:e0191766. doi: 10.1371/journal.pone.0191766
4. Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. (2018) 37:30. doi: 10.1186/s13046-018-0705-7
5. Batta N, Pandey M. Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance. World J Surg Oncol. (2019) 17:198. doi: 10.1186/s12957-019-1741-2
6. Padhi SS, Roy S, Kar M, Saha A, Roy S, Adhya A, et al. Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma. Oral Oncol. (2017) 73:27–35. doi: 10.1016/j.oraloncology.2017.07.030
7. Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A. Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance. J Natl Cancer Inst. (2017) 110:677–81. doi: 10.1093/jnci/djx271
8. Costa V, Kowalski LP, Coutinho-Camillo CM, Begnami MD, Calsavara VF, Neves JI, et al. EGFR amplification and expression in oral squamous cell carcinoma in young adults. Int J Oral Maxillofac Surg. (2018) 47:817–23. doi: 10.1016/j.ijom.2018.01.002
9. Perisanidis C. Prevalence of EGFR tyrosine kinase domain mutations in head and neck squamous cell carcinoma: cohort study and systematic review. In Vivo. (2017) 31:23–34. doi: 10.21873/invivo.11020
10. Aggarwal, Dipanshu, et al. "Pathogenetic Model of Survivin-dependent Molecular Signalling Pathways in Tumorigenesis of Oral Cancer and Precursor Lesions." Journal of Oral and Maxillofacial Pathology : JOMFP, vol. 27, no. 2, 2023, pp. 287-294, https://doi.org/10.4103 /jomfp.jomfp_5_23.
11. Rai P, Acharya S, Tayaar A, Kale J, Hallikeri K. Immunohistochemical expression of p53 and c-Myc at the invasive front of oral squamous cell carcinoma and its relation with clinicopathologic characteristics. Ann Diagn Pathol. 2017;30:28–35
12. Thota R, Aggarwal S, Chirom AS, Thakar A, Gupta SD, Sharma SC, et al. Serum survivin in oral submucosal fibrosis and squamous cell carcinoma. Indian J Otolaryngol Head Neck Surg. 2022;74:2027–32
13. Gayathri C, Rao GV. Immunohistochemical expression of survivin in oral leukoplakia and oral squamous cell carcinoma. J NTR Univ Health Sci. 2019;6:39–44.
14. Negi A, Puri A, Gupta R, Nangia R, Sachdeva A, Mittal M. Comparison of immunohistochemical expression of antiapoptotic protein survivin in normal oral mucosa, oral leukoplakia and oral squamous cell carcinoma. Pathol Res Int. 2015;2015:1–6.
15. Ajithkumar M, Murali CR, Vani NV. Prognostic implication of survivin expression in oral squamous cell carcinoma-An immunohistochemical study. J Contemp Dent Pract. 2019;20:577–81
16. Mehdi RF, Sheikh F, Khan R, Fawad B, Haq AU. Survivin promoter polymorphism (- 31 C/G): A genetic risk factor for oral cancer. Asian Pac J Cancer Prev. 2019;20:1289–93.
17. Khan Z, Khan A, Yadav H, Prasad GBK, Bisen PS. Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett. 2017;22:1–8.
18. Dander, E., Palmi, C., D’Amico, G., & Cazzaniga, G. (2021). The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia. International Journal of Molecular Sciences, 22(9), 4426.
19. Fares, B., Berger, L., Bangiev-Girsh, E., Kakun, R. R., Ghannam-Shahbari, D., Tabach, Y., ... & Perets, R. (2021). PAX8 plays an essential antiapoptotic role in uterine serous papillary cancer. Oncogene, 40(34), 5275-5285.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Nimra Noreen
Lecturer, Department of Oral Pathology, Baqai Medical University, Karachi - Pakistan
Zoya Quddus
Dental Surgeon (B-17), Women and Children Hospital, Mastung Balochistan - Pakistan
Muhammad Masood Ahmad
PhD Biochemistry Scholar, Government College University, Faisalabad - Pakistan
Haroon Amin
PhD Biochemistry Scholar, Government College University, Faisalabad - Pakistan
Muhammad Hassan Sadiq
Allied Health Sciences Department, College of Rehabilitation Science, Faisalabad - Pakistan